Singapore's Juniper Biologics secures distribution rights for Caris Life Sciences' cancer profiling services in the Middle East and Africa.

Singapore-based Juniper Biologics secures distribution rights for Caris Life Sciences' solid tumour molecular profiling services in the Middle East and Africa, following a January 2023 partnership in Southeast Asia. Caris' AI-driven precision medicine helps provide personalized cancer treatments by analyzing DNA, RNA, and proteins. Juniper aims to expand patient access to personalized treatment options across the regions.